Clinical Trial Detail

NCT ID NCT01828034
Title First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center, Novartis
Indications

biliary tract cancer

Therapies

Binimetinib + Cisplatin + Gemcitabine

Age Groups: adult

No variant requirements are available.